#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3. Discussion
1-1	0-2	3.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=Urine is a vital biofluid in mammals and could be easily collected in a noninvasive manner .
2-1	14-19	Urine	substance	new	coref	2-3[3_0]
2-2	20-22	is	_	_	_	_
2-3	23-24	a	substance[3]	giv[3]	coref	3-9[0_3]
2-4	25-30	vital	substance[3]	giv[3]	_	_
2-5	31-39	biofluid	substance[3]	giv[3]	_	_
2-6	40-42	in	substance[3]	giv[3]	_	_
2-7	43-50	mammals	substance[3]|animal	giv[3]|new	_	_
2-8	51-54	and	_	_	_	_
2-9	55-60	could	_	_	_	_
2-10	61-63	be	_	_	_	_
2-11	64-70	easily	_	_	_	_
2-12	71-80	collected	_	_	_	_
2-13	81-83	in	_	_	_	_
2-14	84-85	a	abstract[5]	new[5]	_	_
2-15	86-97	noninvasive	abstract[5]	new[5]	_	_
2-16	98-104	manner	abstract[5]	new[5]	_	_
2-17	105-106	.	_	_	_	_

#Text=Moreover , the metabolites components and concentrations in urine are good indicators of metabolic fluctuations .
3-1	107-115	Moreover	_	_	_	_
3-2	116-117	,	_	_	_	_
3-3	118-121	the	substance[7]	new[7]	_	_
3-4	122-133	metabolites	substance|substance[7]	new|new[7]	coref	20-1
3-5	134-144	components	substance[7]	new[7]	_	_
3-6	145-148	and	_	_	_	_
3-7	149-163	concentrations	abstract[8]	new[8]	coref	3-11[10_8]
3-8	164-166	in	abstract[8]	new[8]	_	_
3-9	167-172	urine	abstract[8]|substance	new[8]|giv	coref	6-15
3-10	173-176	are	_	_	_	_
3-11	177-181	good	abstract[10]	giv[10]	_	_
3-12	182-192	indicators	abstract[10]	giv[10]	_	_
3-13	193-195	of	abstract[10]	giv[10]	_	_
3-14	196-205	metabolic	abstract[10]|quantity|abstract[12]	giv[10]|new|new[12]	coref	4-15
3-15	206-218	fluctuations	abstract[10]|abstract[12]	giv[10]|new[12]	_	_
3-16	219-220	.	_	_	_	_

#Text=Comparison of metabolite profiles between the treatment group and the control group could obtain metabolic changes and reveal adverse effects mechanism of stressor .
4-1	221-231	Comparison	abstract[13]	new[13]	_	_
4-2	232-234	of	abstract[13]	new[13]	_	_
4-3	235-245	metabolite	abstract[13]|substance|object[15]	new[13]|new|new[15]	_	_
4-4	246-254	profiles	abstract[13]|object[15]	new[13]|new[15]	_	_
4-5	255-262	between	abstract[13]|object[15]	new[13]|new[15]	_	_
4-6	263-266	the	abstract[13]|object[15]|place[17]	new[13]|new[15]|new[17]	_	_
4-7	267-276	treatment	abstract[13]|object[15]|abstract|place[17]	new[13]|new[15]|new|new[17]	coref	11-11
4-8	277-282	group	abstract[13]|object[15]|place[17]	new[13]|new[15]|new[17]	_	_
4-9	283-286	and	abstract[13]|object[15]	new[13]|new[15]	_	_
4-10	287-290	the	abstract[13]|object[15]|place[18]	new[13]|new[15]|new[18]	coref	11-7[84_18]
4-11	291-298	control	abstract[13]|object[15]|place[18]	new[13]|new[15]|new[18]	_	_
4-12	299-304	group	abstract[13]|object[15]|place[18]	new[13]|new[15]|new[18]	_	_
4-13	305-310	could	_	_	_	_
4-14	311-317	obtain	_	_	_	_
4-15	318-327	metabolic	person|abstract[20]	giv|new[20]	coref|coref	5-15|6-11[38_20]
4-16	328-335	changes	abstract[20]	new[20]	_	_
4-17	336-339	and	_	_	_	_
4-18	340-346	reveal	_	_	_	_
4-19	347-354	adverse	abstract[22]	new[22]	_	_
4-20	355-362	effects	abstract|abstract[22]	new|new[22]	_	_
4-21	363-372	mechanism	abstract[22]	new[22]	_	_
4-22	373-375	of	abstract[22]	new[22]	_	_
4-23	376-384	stressor	abstract[22]|abstract	new[22]|new	_	_
4-24	385-386	.	_	_	_	_

#Text=In this study , 1H-NMR and UPLC-MS/MS based metabolomics were employed to investigate the metabolic perturbations after rac -metalaxyl and metalaxyl-M exposure .
5-1	387-389	In	_	_	_	_
5-2	390-394	this	abstract[24]	new[24]	_	_
5-3	395-400	study	abstract[24]	new[24]	_	_
5-4	401-402	,	_	_	_	_
5-5	403-409	1H-NMR	person	new	_	_
5-6	410-413	and	_	_	_	_
5-7	414-424	UPLC-MS/MS	person	new	_	_
5-8	425-430	based	_	_	_	_
5-9	431-443	metabolomics	abstract	new	_	_
5-10	444-448	were	_	_	_	_
5-11	449-457	employed	_	_	_	_
5-12	458-460	to	_	_	_	_
5-13	461-472	investigate	_	_	_	_
5-14	473-476	the	abstract[29]	new[29]	_	_
5-15	477-486	metabolic	person|abstract[29]	giv|new[29]	coref	6-12
5-16	487-500	perturbations	abstract[29]	new[29]	_	_
5-17	501-506	after	_	_	_	_
5-18	507-510	rac	substance|abstract[31]	new|new[31]	coref|coref	6-6|12-5[0_31]
5-19	511-521	-metalaxyl	abstract[31]	new[31]	_	_
5-20	522-525	and	abstract[31]	new[31]	_	_
5-21	526-537	metalaxyl-M	abstract[31]	new[31]	_	_
5-22	538-546	exposure	abstract[31]	new[31]	_	_
5-23	547-548	.	_	_	_	_

#Text=The results showed that both rac -metalaxyl and metalaxyl-M induced systematic metabolic changes in urine and serum .
6-1	549-552	The	abstract[32]	new[32]	coref	14-1[106_32]
6-2	553-560	results	abstract[32]	new[32]	_	_
6-3	561-567	showed	_	_	_	_
6-4	568-572	that	_	_	_	_
6-5	573-577	both	abstract[34]|abstract[35]	new[34]|new[35]	coref|coref	13-5[99_34]|13-5[100_35]
6-6	578-581	rac	substance|abstract[34]|abstract[35]	giv|new[34]|new[35]	coref	12-22
6-7	582-592	-metalaxyl	abstract[34]|abstract[35]	new[34]|new[35]	_	_
6-8	593-596	and	abstract[35]	new[35]	_	_
6-9	597-608	metalaxyl-M	abstract[35]|substance	new[35]|new	coref	7-4
6-10	609-616	induced	_	_	_	_
6-11	617-627	systematic	abstract[38]	giv[38]	coref	7-9[46_38]
6-12	628-637	metabolic	person|abstract[38]	giv|giv[38]	_	_
6-13	638-645	changes	abstract[38]	giv[38]	_	_
6-14	646-648	in	abstract[38]	giv[38]	_	_
6-15	649-654	urine	abstract[38]|substance	giv[38]|giv	coref	20-10[137_0]
6-16	655-658	and	abstract[38]	giv[38]	_	_
6-17	659-664	serum	abstract[38]|substance	giv[38]|new	_	_
6-18	665-666	.	_	_	_	_

#Text=Rac -metalaxyl and metalaxyl-M induced liver damages and metabolic pathway changes including glycine , serine , and threonine metabolism , citrate cycle ( TCA cycle ) , pyruvate metabolism , glycolysis or gluconeogenesis , glycerophospholipid metabolism , and glyoxylate and dicarboxylate metabolism .
7-1	667-670	Rac	substance	new	_	_
7-2	671-681	-metalaxyl	_	_	_	_
7-3	682-685	and	_	_	_	_
7-4	686-697	metalaxyl-M	substance	giv	coref	13-8
7-5	698-705	induced	_	_	_	_
7-6	706-711	liver	object|abstract[44]	new|new[44]	coref|coref	10-5|17-1[126_44]
7-7	712-719	damages	abstract[44]	new[44]	_	_
7-8	720-723	and	_	_	_	_
7-9	724-733	metabolic	abstract[46]	giv[46]	coref	10-1[78_46]
7-10	734-741	pathway	place|abstract[46]	new|giv[46]	_	_
7-11	742-749	changes	abstract[46]	giv[46]	_	_
7-12	750-759	including	abstract[46]	giv[46]	_	_
7-13	760-767	glycine	abstract[46]|substance	giv[46]|new	_	_
7-14	768-769	,	abstract[46]	giv[46]	_	_
7-15	770-776	serine	abstract[46]|substance	giv[46]|new	_	_
7-16	777-778	,	abstract[46]	giv[46]	_	_
7-17	779-782	and	abstract[46]	giv[46]	_	_
7-18	783-792	threonine	abstract[46]|object|abstract[50]	giv[46]|new|new[50]	coref	7-28[56_50]
7-19	793-803	metabolism	abstract[46]|abstract[50]	giv[46]|new[50]	_	_
7-20	804-805	,	abstract[46]	giv[46]	_	_
7-21	806-813	citrate	abstract[46]|person|abstract[52]	giv[46]|new|new[52]	appos|coref	7-24[54_52]|20-20
7-22	814-819	cycle	abstract[46]|abstract[52]	giv[46]|new[52]	_	_
7-23	820-821	(	abstract[46]	giv[46]	_	_
7-24	822-825	TCA	abstract[46]|abstract|abstract[54]	giv[46]|new|giv[54]	coref|coref	21-12|21-11[153_54]
7-25	826-831	cycle	abstract[46]|abstract[54]	giv[46]|giv[54]	_	_
7-26	832-833	)	abstract[46]	giv[46]	_	_
7-27	834-835	,	abstract[46]	giv[46]	_	_
7-28	836-844	pyruvate	abstract[46]|object|abstract[56]|abstract[57]	giv[46]|new|giv[56]|new[57]	coref|coref|coref	7-35[61_56]|16-10[120_57]|20-28
7-29	845-855	metabolism	abstract[46]|abstract[56]|abstract[57]	giv[46]|giv[56]|new[57]	_	_
7-30	856-857	,	abstract[46]|abstract[57]	giv[46]|new[57]	_	_
7-31	858-868	glycolysis	abstract[46]|abstract[57]|substance	giv[46]|new[57]|new	coref	21-19
7-32	869-871	or	abstract[46]	giv[46]	_	_
7-33	872-887	gluconeogenesis	abstract[46]|substance	giv[46]|new	coref	21-21
7-34	888-889	,	abstract[46]	giv[46]	_	_
7-35	890-909	glycerophospholipid	abstract[46]|object|abstract[61]	giv[46]|new|giv[61]	coref	7-41[64_61]
7-36	910-920	metabolism	abstract[46]|abstract[61]	giv[46]|giv[61]	_	_
7-37	921-922	,	abstract[46]	giv[46]	_	_
7-38	923-926	and	abstract[46]	giv[46]	_	_
7-39	927-937	glyoxylate	abstract[46]|substance	giv[46]|new	_	_
7-40	938-941	and	abstract[46]	giv[46]	_	_
7-41	942-955	dicarboxylate	abstract[46]|object|abstract[64]	giv[46]|new|giv[64]	coref	8-7[67_64]
7-42	956-966	metabolism	abstract[46]|abstract[64]	giv[46]|giv[64]	_	_
7-43	967-968	.	_	_	_	_

#Text=These pathways are highly related to energy metabolism , lipid metabolism , amino acids metabolism , microbial metabolism , and tryptophan metabolism .
8-1	969-974	These	place[65]	new[65]	coref	21-7[151_65]
8-2	975-983	pathways	place[65]	new[65]	_	_
8-3	984-987	are	_	_	_	_
8-4	988-994	highly	_	_	_	_
8-5	995-1002	related	_	_	_	_
8-6	1003-1005	to	_	_	_	_
8-7	1006-1012	energy	substance|abstract[67]	new|giv[67]	coref|coref	8-10[69_67]|19-1
8-8	1013-1023	metabolism	abstract[67]	giv[67]	_	_
8-9	1024-1025	,	_	_	_	_
8-10	1026-1031	lipid	object|abstract[69]	new|giv[69]	coref	8-13[71_69]
8-11	1032-1042	metabolism	abstract[69]	giv[69]	_	_
8-12	1043-1044	,	_	_	_	_
8-13	1045-1050	amino	abstract[71]	giv[71]	coref	8-17[72_71]
8-14	1051-1056	acids	object|abstract[71]	new|giv[71]	_	_
8-15	1057-1067	metabolism	abstract[71]	giv[71]	_	_
8-16	1068-1069	,	_	_	_	_
8-17	1070-1079	microbial	abstract[72]	giv[72]	coref	8-21[74_72]
8-18	1080-1090	metabolism	abstract[72]	giv[72]	_	_
8-19	1091-1092	,	_	_	_	_
8-20	1093-1096	and	_	_	_	_
8-21	1097-1107	tryptophan	object|abstract[74]	new|giv[74]	coref	16-10[0_74]
8-22	1108-1118	metabolism	abstract[74]	giv[74]	_	_
8-23	1119-1120	.	_	_	_	_

#Text=3.1 .
9-1	1121-1124	3.1	abstract	new	_	_
9-2	1125-1126	.	_	_	_	_

#Text=Body Weight Changes and Liver Damage
10-1	1127-1131	Body	object|person[77]|abstract[78]	new|new[77]|giv[78]	coref|coref	12-7[88_78]|12-11
10-2	1132-1138	Weight	person[77]|abstract[78]	new[77]|giv[78]	_	_
10-3	1139-1146	Changes	person[77]|abstract[78]	new[77]|giv[78]	_	_
10-4	1147-1150	and	abstract[78]	giv[78]	_	_
10-5	1151-1156	Liver	abstract[78]|object|abstract[80]	giv[78]|giv|new[80]	coref|coref	14-10|15-5[114_80]
10-6	1157-1163	Damage	abstract[78]|abstract[80]	giv[78]|new[80]	_	_

#Text=Only one mouse was dead in the 60 mg/kg metalaxyl-M treatment group during the whole experiment .
11-1	1164-1168	Only	animal[81]	new[81]	_	_
11-2	1169-1172	one	animal[81]	new[81]	_	_
11-3	1173-1178	mouse	animal[81]	new[81]	_	_
11-4	1179-1182	was	_	_	_	_
11-5	1183-1187	dead	_	_	_	_
11-6	1188-1190	in	_	_	_	_
11-7	1191-1194	the	place[84]	giv[84]	_	_
11-8	1195-1197	60	quantity[82]|place[84]	new[82]|giv[84]	_	_
11-9	1198-1203	mg/kg	quantity[82]|place[84]	new[82]|giv[84]	_	_
11-10	1204-1215	metalaxyl-M	place[84]	giv[84]	_	_
11-11	1216-1225	treatment	abstract|place[84]	giv|giv[84]	coref	12-19
11-12	1226-1231	group	place[84]	giv[84]	_	_
11-13	1232-1238	during	place[84]	giv[84]	_	_
11-14	1239-1242	the	place[84]|event[85]	giv[84]|new[85]	_	_
11-15	1243-1248	whole	place[84]|event[85]	giv[84]|new[85]	_	_
11-16	1249-1259	experiment	place[84]|event[85]	giv[84]|new[85]	_	_
11-17	1260-1261	.	_	_	_	_

#Text=After four weeks of exposure , no significant changes in body weight were observed between the control and treatment groups after rac -metalaxyl and metalaxyl-M exposure .
12-1	1262-1267	After	_	_	_	_
12-2	1268-1272	four	time[86]	new[86]	_	_
12-3	1273-1278	weeks	time[86]	new[86]	_	_
12-4	1279-1281	of	time[86]	new[86]	_	_
12-5	1282-1290	exposure	time[86]|abstract	new[86]|giv	coref	12-22[95_0]
12-6	1291-1292	,	_	_	_	_
12-7	1293-1295	no	abstract[88]	giv[88]	_	_
12-8	1296-1307	significant	abstract[88]	giv[88]	_	_
12-9	1308-1315	changes	abstract[88]	giv[88]	_	_
12-10	1316-1318	in	abstract[88]	giv[88]	_	_
12-11	1319-1323	body	abstract[88]|object|abstract[90]	giv[88]|giv|new[90]	_	_
12-12	1324-1330	weight	abstract[88]|abstract[90]	giv[88]|new[90]	_	_
12-13	1331-1335	were	_	_	_	_
12-14	1336-1344	observed	_	_	_	_
12-15	1345-1352	between	_	_	_	_
12-16	1353-1356	the	abstract[91]	new[91]	_	_
12-17	1357-1364	control	abstract[91]	new[91]	_	_
12-18	1365-1368	and	_	_	_	_
12-19	1369-1378	treatment	event|person[93]	giv|new[93]	_	_
12-20	1379-1385	groups	person[93]	new[93]	_	_
12-21	1386-1391	after	_	_	_	_
12-22	1392-1395	rac	substance|abstract[95]	giv|giv[95]	coref|coref	13-5|14-4[108_95]
12-23	1396-1406	-metalaxyl	abstract[95]	giv[95]	_	_
12-24	1407-1410	and	abstract[95]	giv[95]	_	_
12-25	1411-1422	metalaxyl-M	abstract[95]	giv[95]	_	_
12-26	1423-1431	exposure	abstract[95]	giv[95]	_	_
12-27	1432-1433	.	_	_	_	_

#Text=Histopathology examination showed that rac -metalaxyl and metalaxyl-M can both induce hepatocellular inflammation , necrosis , and vacuolation in mice .
13-1	1434-1448	Histopathology	place|abstract[97]	new|new[97]	_	_
13-2	1449-1460	examination	abstract[97]	new[97]	_	_
13-3	1461-1467	showed	_	_	_	_
13-4	1468-1472	that	_	_	_	_
13-5	1473-1476	rac	substance|abstract[99]|abstract[100]	giv|giv[99]|giv[100]	coref|coref|coref	14-4|20-13[139_99]|20-13[140_100]
13-6	1477-1487	-metalaxyl	abstract[99]|abstract[100]	giv[99]|giv[100]	_	_
13-7	1488-1491	and	abstract[100]	giv[100]	_	_
13-8	1492-1503	metalaxyl-M	abstract[100]|substance	giv[100]|giv	coref	15-3
13-9	1504-1507	can	_	_	_	_
13-10	1508-1512	both	_	_	_	_
13-11	1513-1519	induce	_	_	_	_
13-12	1520-1534	hepatocellular	abstract[102]	new[102]	_	_
13-13	1535-1547	inflammation	abstract[102]	new[102]	_	_
13-14	1548-1549	,	_	_	_	_
13-15	1550-1558	necrosis	event	new	_	_
13-16	1559-1560	,	_	_	_	_
13-17	1561-1564	and	_	_	_	_
13-18	1565-1576	vacuolation	abstract[104]	new[104]	_	_
13-19	1577-1579	in	abstract[104]	new[104]	_	_
13-20	1580-1584	mice	abstract[104]|animal	new[104]|new	coref	14-13
13-21	1585-1586	.	_	_	_	_

#Text=Such results suggested rac -metalaxyl and metalaxyl-M exposure caused liver dysfunction in mice .
14-1	1587-1591	Such	abstract[106]	giv[106]	coref	28-5[208_106]
14-2	1592-1599	results	abstract[106]	giv[106]	_	_
14-3	1600-1609	suggested	_	_	_	_
14-4	1610-1613	rac	substance|abstract[108]	giv|giv[108]	coref|coref	15-9|20-16[142_108]
14-5	1614-1624	-metalaxyl	abstract[108]	giv[108]	_	_
14-6	1625-1628	and	abstract[108]	giv[108]	_	_
14-7	1629-1640	metalaxyl-M	abstract[108]	giv[108]	_	_
14-8	1641-1649	exposure	abstract[108]	giv[108]	_	_
14-9	1650-1656	caused	_	_	_	_
14-10	1657-1662	liver	object|abstract[110]	giv|new[110]	coref	15-6
14-11	1663-1674	dysfunction	abstract[110]	new[110]	_	_
14-12	1675-1677	in	_	_	_	_
14-13	1678-1682	mice	animal	giv	coref	17-12
14-14	1683-1684	.	_	_	_	_

#Text=Moreover , metalaxyl-M induced greater liver damage than rac -metalaxyl at the same dosage .
15-1	1685-1693	Moreover	_	_	_	_
15-2	1694-1695	,	_	_	_	_
15-3	1696-1707	metalaxyl-M	substance	giv	coref	20-16
15-4	1708-1715	induced	_	_	_	_
15-5	1716-1723	greater	abstract[114]	giv[114]	_	_
15-6	1724-1729	liver	object|abstract[114]	giv|giv[114]	coref	16-1[117_0]
15-7	1730-1736	damage	abstract[114]	giv[114]	_	_
15-8	1737-1741	than	abstract[114]	giv[114]	_	_
15-9	1742-1745	rac	abstract[114]|substance	giv[114]|giv	coref	20-13
15-10	1746-1756	-metalaxyl	abstract[116]	new[116]	_	_
15-11	1757-1759	at	abstract[116]	new[116]	_	_
15-12	1760-1763	the	abstract[116]	new[116]	_	_
15-13	1764-1768	same	abstract[116]	new[116]	_	_
15-14	1769-1775	dosage	abstract[116]	new[116]	_	_
15-15	1776-1777	.	_	_	_	_

#Text=The liver is a fundamental and essential organ for metabolism and detoxification of xenobiotics with abundant cytochrome P450 enzymes .
16-1	1778-1781	The	object[117]	giv[117]	coref	16-4[118_117]
16-2	1782-1787	liver	object[117]	giv[117]	_	_
16-3	1788-1790	is	_	_	_	_
16-4	1791-1792	a	object[118]	giv[118]	coref	17-4[127_118]
16-5	1793-1804	fundamental	object[118]	giv[118]	_	_
16-6	1805-1808	and	object[118]	giv[118]	_	_
16-7	1809-1818	essential	object[118]	giv[118]	_	_
16-8	1819-1824	organ	object[118]	giv[118]	_	_
16-9	1825-1828	for	object[118]	giv[118]	_	_
16-10	1829-1839	metabolism	object[118]|abstract|abstract[120]	giv[118]|giv|giv[120]	coref	19-1[132_0]
16-11	1840-1843	and	object[118]|abstract[120]	giv[118]|giv[120]	_	_
16-12	1844-1858	detoxification	object[118]|abstract[120]|abstract[121]	giv[118]|giv[120]|new[121]	_	_
16-13	1859-1861	of	object[118]|abstract[120]|abstract[121]	giv[118]|giv[120]|new[121]	_	_
16-14	1862-1873	xenobiotics	object[118]|abstract[120]|abstract[121]|substance[122]	giv[118]|giv[120]|new[121]|new[122]	_	_
16-15	1874-1878	with	object[118]|abstract[120]|abstract[121]|substance[122]	giv[118]|giv[120]|new[121]|new[122]	_	_
16-16	1879-1887	abundant	object[118]|abstract[120]|abstract[121]|substance[122]|abstract[125]	giv[118]|giv[120]|new[121]|new[122]|new[125]	coref	23-28[176_125]
16-17	1888-1898	cytochrome	object[118]|abstract[120]|abstract[121]|substance[122]|abstract|abstract[125]	giv[118]|giv[120]|new[121]|new[122]|new|new[125]	_	_
16-18	1899-1903	P450	object[118]|abstract[120]|abstract[121]|substance[122]|abstract|abstract[125]	giv[118]|giv[120]|new[121]|new[122]|new|new[125]	_	_
16-19	1904-1911	enzymes	object[118]|abstract[120]|abstract[121]|substance[122]|abstract[125]	giv[118]|giv[120]|new[121]|new[122]|new[125]	_	_
16-20	1912-1913	.	_	_	_	_

#Text=The damages of the liver may greatly affect the detoxification of mice .
17-1	1914-1917	The	abstract[126]	giv[126]	_	_
17-2	1918-1925	damages	abstract[126]	giv[126]	_	_
17-3	1926-1928	of	abstract[126]	giv[126]	_	_
17-4	1929-1932	the	abstract[126]|object[127]	giv[126]|giv[127]	coref	22-18[0_127]
17-5	1933-1938	liver	abstract[126]|object[127]	giv[126]|giv[127]	_	_
17-6	1939-1942	may	_	_	_	_
17-7	1943-1950	greatly	_	_	_	_
17-8	1951-1957	affect	_	_	_	_
17-9	1958-1961	the	abstract[128]	new[128]	_	_
17-10	1962-1976	detoxification	abstract[128]	new[128]	_	_
17-11	1977-1979	of	abstract[128]	new[128]	_	_
17-12	1980-1984	mice	abstract[128]|animal	new[128]|giv	coref	20-10
17-13	1985-1986	.	_	_	_	_

#Text=3.2 .
18-1	1987-1990	3.2	abstract	new	_	_
18-2	1991-1992	.	_	_	_	_

#Text=Energy Metabolism
19-1	1993-1999	Energy	abstract|abstract[132]	giv|giv[132]	coref|coref	20-4|20-4[135_132]
19-2	2000-2010	Metabolism	abstract[132]	giv[132]	_	_

#Text=Metabolites involved in energy metabolism were significant changed in mice urine after rac -metalaxyl and metalaxyl-M exposure , including citrate , succinate , lactate , alanine , pyruvate , and acetate .
20-1	2011-2022	Metabolites	substance	giv	coref	21-1[149_0]
20-2	2023-2031	involved	_	_	_	_
20-3	2032-2034	in	_	_	_	_
20-4	2035-2041	energy	substance|abstract[135]	giv|giv[135]	coref|coref	21-7|21-15[155_135]
20-5	2042-2052	metabolism	abstract[135]	giv[135]	_	_
20-6	2053-2057	were	_	_	_	_
20-7	2058-2069	significant	_	_	_	_
20-8	2070-2077	changed	_	_	_	_
20-9	2078-2080	in	_	_	_	_
20-10	2081-2085	mice	animal|substance[137]	giv|giv[137]	coref|coref	23-16[171_137]|23-19[172_0]
20-11	2086-2091	urine	substance[137]	giv[137]	_	_
20-12	2092-2097	after	substance[137]	giv[137]	_	_
20-13	2098-2101	rac	substance[137]|substance|abstract[139]|abstract[140]	giv[137]|giv|giv[139]|giv[140]	coref|coref|coref	28-16|28-16[214_139]|28-16[215_140]
20-14	2102-2112	-metalaxyl	substance[137]|abstract[139]|abstract[140]	giv[137]|giv[139]|giv[140]	_	_
20-15	2113-2116	and	substance[137]|abstract[140]	giv[137]|giv[140]	_	_
20-16	2117-2128	metalaxyl-M	substance[137]|abstract[140]|substance|abstract[142]	giv[137]|giv[140]|giv|giv[142]	coref|coref	23-23|28-19[216_142]
20-17	2129-2137	exposure	substance[137]|abstract[140]|abstract[142]	giv[137]|giv[140]|giv[142]	_	_
20-18	2138-2139	,	substance[137]|abstract[140]|abstract[142]	giv[137]|giv[140]|giv[142]	_	_
20-19	2140-2149	including	substance[137]|abstract[140]|abstract[142]	giv[137]|giv[140]|giv[142]	_	_
20-20	2150-2157	citrate	substance[137]|abstract[140]|abstract[142]|substance	giv[137]|giv[140]|giv[142]|giv	coref	22-1
20-21	2158-2159	,	substance[137]|abstract[140]|abstract[142]	giv[137]|giv[140]|giv[142]	_	_
20-22	2160-2169	succinate	substance[137]|abstract[140]|abstract[142]|substance	giv[137]|giv[140]|giv[142]|new	coref	22-3
20-23	2170-2171	,	substance[137]|abstract[140]|abstract[142]	giv[137]|giv[140]|giv[142]	_	_
20-24	2172-2179	lactate	substance[137]|abstract[140]|abstract[142]|substance	giv[137]|giv[140]|giv[142]|new	coref	24-13
20-25	2180-2181	,	substance[137]|abstract[140]|abstract[142]	giv[137]|giv[140]|giv[142]	_	_
20-26	2182-2189	alanine	substance[137]|abstract[140]|abstract[142]|substance	giv[137]|giv[140]|giv[142]|new	coref	24-15
20-27	2190-2191	,	substance[137]|abstract[140]|abstract[142]	giv[137]|giv[140]|giv[142]	_	_
20-28	2192-2200	pyruvate	substance[137]|abstract[140]|abstract[142]|substance	giv[137]|giv[140]|giv[142]|giv	coref	21-15
20-29	2201-2202	,	substance[137]|abstract[140]|abstract[142]	giv[137]|giv[140]|giv[142]	_	_
20-30	2203-2206	and	substance[137]|abstract[140]|abstract[142]	giv[137]|giv[140]|giv[142]	_	_
20-31	2207-2214	acetate	substance[137]|abstract[140]|abstract[142]|substance	giv[137]|giv[140]|giv[142]|new	_	_
20-32	2215-2216	.	_	_	_	_

#Text=These metabolites are highly related to energy pathways , including the TCA cycle , pyruvate metabolism , and glycolysis or gluconeogenesis .
21-1	2217-2222	These	substance[149]	giv[149]	coref	36-1[256_149]
21-2	2223-2234	metabolites	substance[149]	giv[149]	_	_
21-3	2235-2238	are	_	_	_	_
21-4	2239-2245	highly	_	_	_	_
21-5	2246-2253	related	_	_	_	_
21-6	2254-2256	to	_	_	_	_
21-7	2257-2263	energy	abstract|place[151]	giv|giv[151]	coref	23-41
21-8	2264-2272	pathways	place[151]	giv[151]	_	_
21-9	2273-2274	,	place[151]	giv[151]	_	_
21-10	2275-2284	including	place[151]	giv[151]	_	_
21-11	2285-2288	the	place[151]|abstract[153]	giv[151]|giv[153]	coref	22-9[163_153]
21-12	2289-2292	TCA	place[151]|abstract|abstract[153]	giv[151]|giv|giv[153]	coref	22-10
21-13	2293-2298	cycle	place[151]|abstract[153]	giv[151]|giv[153]	_	_
21-14	2299-2300	,	place[151]	giv[151]	_	_
21-15	2301-2309	pyruvate	place[151]|object|abstract[155]	giv[151]|giv|giv[155]	coref|coref	23-41[181_155]|24-8
21-16	2310-2320	metabolism	place[151]|abstract[155]	giv[151]|giv[155]	_	_
21-17	2321-2322	,	place[151]	giv[151]	_	_
21-18	2323-2326	and	place[151]	giv[151]	_	_
21-19	2327-2337	glycolysis	place[151]|substance	giv[151]|giv	_	_
21-20	2338-2340	or	place[151]	giv[151]	_	_
21-21	2341-2356	gluconeogenesis	place[151]|substance	giv[151]|giv	_	_
21-22	2357-2358	.	_	_	_	_

#Text=Citrate and succinate are the main intermediates in the TCA cycle , which is mainly appeared in liver mitochondria .
22-1	2359-2366	Citrate	substance|substance[159]	giv|new[159]	coref|coref	23-12|23-12[169_159]
22-2	2367-2370	and	substance[159]	new[159]	_	_
22-3	2371-2380	succinate	substance[159]|substance	new[159]|giv	coref	22-5[161_0]
22-4	2381-2384	are	_	_	_	_
22-5	2385-2388	the	substance[161]	giv[161]	coref	23-14[0_161]
22-6	2389-2393	main	substance[161]	giv[161]	_	_
22-7	2394-2407	intermediates	substance[161]	giv[161]	_	_
22-8	2408-2410	in	substance[161]	giv[161]	_	_
22-9	2411-2414	the	substance[161]|abstract[163]	giv[161]|giv[163]	coref	23-32[178_163]
22-10	2415-2418	TCA	substance[161]|abstract|abstract[163]	giv[161]|giv|giv[163]	coref	23-33
22-11	2419-2424	cycle	substance[161]|abstract[163]	giv[161]|giv[163]	_	_
22-12	2425-2426	,	_	_	_	_
22-13	2427-2432	which	_	_	_	_
22-14	2433-2435	is	_	_	_	_
22-15	2436-2442	mainly	_	_	_	_
22-16	2443-2451	appeared	_	_	_	_
22-17	2452-2454	in	_	_	_	_
22-18	2455-2460	liver	object|place[165]	giv|new[165]	coref	23-28[0_165]
22-19	2461-2473	mitochondria	place[165]	new[165]	_	_
22-20	2474-2475	.	_	_	_	_

#Text=Although other factors cannot be excluded , the increased levels of citrate and succinate in the urine of metalaxyl-M-treated mice indicated that metalaxyl-M affected the activity of mitochondria enzymes involved in the TCA cycle , resulting in the enhancement of energy metabolism in treated mice .
23-1	2476-2484	Although	_	_	_	_
23-2	2485-2490	other	abstract[166]	new[166]	_	_
23-3	2491-2498	factors	abstract[166]	new[166]	_	_
23-4	2499-2505	cannot	_	_	_	_
23-5	2506-2508	be	_	_	_	_
23-6	2509-2517	excluded	_	_	_	_
23-7	2518-2519	,	_	_	_	_
23-8	2520-2523	the	abstract[167]	new[167]	_	_
23-9	2524-2533	increased	abstract[167]	new[167]	_	_
23-10	2534-2540	levels	abstract[167]	new[167]	_	_
23-11	2541-2543	of	abstract[167]	new[167]	_	_
23-12	2544-2551	citrate	abstract[167]|substance|substance[169]	new[167]|giv|giv[169]	coref	25-21
23-13	2552-2555	and	abstract[167]|substance[169]	new[167]|giv[169]	_	_
23-14	2556-2565	succinate	abstract[167]|substance[169]|substance	new[167]|giv[169]|giv	_	_
23-15	2566-2568	in	abstract[167]	new[167]	_	_
23-16	2569-2572	the	abstract[167]|substance[171]	new[167]|giv[171]	coref	39-5[0_171]
23-17	2573-2578	urine	abstract[167]|substance[171]	new[167]|giv[171]	_	_
23-18	2579-2581	of	abstract[167]|substance[171]	new[167]|giv[171]	_	_
23-19	2582-2601	metalaxyl-M-treated	abstract[167]|substance[171]|animal[172]	new[167]|giv[171]|giv[172]	coref	23-44[182_172]
23-20	2602-2606	mice	abstract[167]|substance[171]|animal[172]	new[167]|giv[171]|giv[172]	_	_
23-21	2607-2616	indicated	_	_	_	_
23-22	2617-2621	that	_	_	_	_
23-23	2622-2633	metalaxyl-M	substance	giv	coref	32-5
23-24	2634-2642	affected	_	_	_	_
23-25	2643-2646	the	abstract[174]	new[174]	_	_
23-26	2647-2655	activity	abstract[174]	new[174]	_	_
23-27	2656-2658	of	abstract[174]	new[174]	_	_
23-28	2659-2671	mitochondria	abstract[174]|place|abstract[176]	new[174]|giv|giv[176]	_	_
23-29	2672-2679	enzymes	abstract[174]|abstract[176]	new[174]|giv[176]	_	_
23-30	2680-2688	involved	_	_	_	_
23-31	2689-2691	in	_	_	_	_
23-32	2692-2695	the	abstract[178]	giv[178]	_	_
23-33	2696-2699	TCA	abstract|abstract[178]	giv|giv[178]	_	_
23-34	2700-2705	cycle	abstract[178]	giv[178]	_	_
23-35	2706-2707	,	_	_	_	_
23-36	2708-2717	resulting	_	_	_	_
23-37	2718-2720	in	_	_	_	_
23-38	2721-2724	the	abstract[179]	new[179]	_	_
23-39	2725-2736	enhancement	abstract[179]	new[179]	_	_
23-40	2737-2739	of	abstract[179]	new[179]	_	_
23-41	2740-2746	energy	abstract[179]|substance|abstract[181]	new[179]|giv|giv[181]	coref|coref	24-20[190_181]|27-18
23-42	2747-2757	metabolism	abstract[179]|abstract[181]	new[179]|giv[181]	_	_
23-43	2758-2760	in	abstract[179]|abstract[181]	new[179]|giv[181]	_	_
23-44	2761-2768	treated	abstract[179]|abstract[181]|animal[182]	new[179]|giv[181]|giv[182]	coref	28-14[0_182]
23-45	2769-2773	mice	abstract[179]|abstract[181]|animal[182]	new[179]|giv[181]|giv[182]	_	_
23-46	2774-2775	.	_	_	_	_

#Text=In addition , the decreased level of pyruvate and increased levels of lactate and alanine were highly related to pyruvate metabolism .
24-1	2776-2778	In	_	_	_	_
24-2	2779-2787	addition	_	_	_	_
24-3	2788-2789	,	_	_	_	_
24-4	2790-2793	the	abstract[183]	new[183]	_	_
24-5	2794-2803	decreased	abstract[183]	new[183]	_	_
24-6	2804-2809	level	abstract[183]	new[183]	_	_
24-7	2810-2812	of	abstract[183]	new[183]	_	_
24-8	2813-2821	pyruvate	abstract[183]|substance	new[183]|giv	coref	24-20
24-9	2822-2825	and	_	_	_	_
24-10	2826-2835	increased	_	_	_	_
24-11	2836-2842	levels	abstract[185]	new[185]	_	_
24-12	2843-2845	of	abstract[185]	new[185]	_	_
24-13	2846-2853	lactate	abstract[185]|substance|substance[187]	new[185]|giv|new[187]	coref|coref	26-1|26-1[198_187]
24-14	2854-2857	and	abstract[185]|substance[187]	new[185]|new[187]	_	_
24-15	2858-2865	alanine	abstract[185]|substance[187]|substance	new[185]|new[187]|giv	coref	26-3
24-16	2866-2870	were	_	_	_	_
24-17	2871-2877	highly	_	_	_	_
24-18	2878-2885	related	_	_	_	_
24-19	2886-2888	to	_	_	_	_
24-20	2889-2897	pyruvate	object|abstract[190]	giv|giv[190]	coref|coref	25-1|27-17[207_190]
24-21	2898-2908	metabolism	abstract[190]	giv[190]	_	_
24-22	2909-2910	.	_	_	_	_

#Text=Pyruvate could be converted to acetyl-coenzyme A ( COA ) , which is a vital intermediate in the synthesis of citrate .
25-1	2911-2919	Pyruvate	substance	giv	coref	26-9
25-2	2920-2925	could	_	_	_	_
25-3	2926-2928	be	_	_	_	_
25-4	2929-2938	converted	_	_	_	_
25-5	2939-2941	to	_	_	_	_
25-6	2942-2957	acetyl-coenzyme	substance	new	appos	25-7[193_0]
25-7	2958-2959	A	substance[193]	giv[193]	_	_
25-8	2960-2961	(	substance[193]	giv[193]	_	_
25-9	2962-2965	COA	substance[193]	giv[193]	_	_
25-10	2966-2967	)	substance[193]	giv[193]	_	_
25-11	2968-2969	,	_	_	_	_
25-12	2970-2975	which	_	_	_	_
25-13	2976-2978	is	_	_	_	_
25-14	2979-2980	a	organization[194]	new[194]	_	_
25-15	2981-2986	vital	organization[194]	new[194]	_	_
25-16	2987-2999	intermediate	organization[194]	new[194]	_	_
25-17	3000-3002	in	organization[194]	new[194]	_	_
25-18	3003-3006	the	organization[194]|abstract[195]	new[194]|new[195]	coref	37-16[270_195]
25-19	3007-3016	synthesis	organization[194]|abstract[195]	new[194]|new[195]	_	_
25-20	3017-3019	of	organization[194]|abstract[195]	new[194]|new[195]	_	_
25-21	3020-3027	citrate	organization[194]|abstract[195]|substance	new[194]|new[195]|giv	_	_
25-22	3028-3029	.	_	_	_	_

#Text=Lactate and alanine can also be converted to pyruvate .
26-1	3030-3037	Lactate	substance|substance[198]	giv|giv[198]	coref|coref	27-3[201_0]|27-3[202_198]
26-2	3038-3041	and	substance[198]	giv[198]	_	_
26-3	3042-3049	alanine	substance[198]|substance	giv[198]|giv	coref	27-7
26-4	3050-3053	can	_	_	_	_
26-5	3054-3058	also	_	_	_	_
26-6	3059-3061	be	_	_	_	_
26-7	3062-3071	converted	_	_	_	_
26-8	3072-3074	to	_	_	_	_
26-9	3075-3083	pyruvate	substance	giv	_	_
26-10	3084-3085	.	_	_	_	_

#Text=Thus , the increased lactate and alanine could promote the level of acetyl-COA and then up-regulate the energy metabolism .
27-1	3086-3090	Thus	_	_	_	_
27-2	3091-3092	,	_	_	_	_
27-3	3093-3096	the	substance[201]|substance[202]	giv[201]|giv[202]	_	_
27-4	3097-3106	increased	substance[201]|substance[202]	giv[201]|giv[202]	_	_
27-5	3107-3114	lactate	substance[201]|substance[202]	giv[201]|giv[202]	_	_
27-6	3115-3118	and	substance[202]	giv[202]	_	_
27-7	3119-3126	alanine	substance[202]|substance	giv[202]|giv	_	_
27-8	3127-3132	could	_	_	_	_
27-9	3133-3140	promote	_	_	_	_
27-10	3141-3144	the	abstract[204]	new[204]	_	_
27-11	3145-3150	level	abstract[204]	new[204]	_	_
27-12	3151-3153	of	abstract[204]	new[204]	_	_
27-13	3154-3164	acetyl-COA	abstract[204]|substance	new[204]|new	_	_
27-14	3165-3168	and	_	_	_	_
27-15	3169-3173	then	_	_	_	_
27-16	3174-3185	up-regulate	_	_	_	_
27-17	3186-3189	the	abstract[207]	giv[207]	coref	28-11[211_207]
27-18	3190-3196	energy	substance|abstract[207]	giv|giv[207]	coref	28-11
27-19	3197-3207	metabolism	abstract[207]	giv[207]	_	_
27-20	3208-3209	.	_	_	_	_

#Text=To sum up , these results indicated the enhancement of energy metabolism in mice after rac -metalaxyl and metalaxyl-M exposure .
28-1	3210-3212	To	_	_	_	_
28-2	3213-3216	sum	_	_	_	_
28-3	3217-3219	up	_	_	_	_
28-4	3220-3221	,	_	_	_	_
28-5	3222-3227	these	abstract[208]	giv[208]	_	_
28-6	3228-3235	results	abstract[208]	giv[208]	_	_
28-7	3236-3245	indicated	_	_	_	_
28-8	3246-3249	the	abstract[209]	new[209]	_	_
28-9	3250-3261	enhancement	abstract[209]	new[209]	_	_
28-10	3262-3264	of	abstract[209]	new[209]	_	_
28-11	3265-3271	energy	abstract[209]|substance|abstract[211]	new[209]|giv|giv[211]	coref|coref	29-15|29-15[223_211]
28-12	3272-3282	metabolism	abstract[209]|abstract[211]	new[209]|giv[211]	_	_
28-13	3283-3285	in	abstract[209]|abstract[211]	new[209]|giv[211]	_	_
28-14	3286-3290	mice	abstract[209]|abstract[211]|animal	new[209]|giv[211]|giv	_	_
28-15	3291-3296	after	_	_	_	_
28-16	3297-3300	rac	substance|abstract[214]|abstract[215]	giv|giv[214]|giv[215]	coref	29-12
28-17	3301-3311	-metalaxyl	abstract[214]|abstract[215]	giv[214]|giv[215]	_	_
28-18	3312-3315	and	abstract[215]	giv[215]	_	_
28-19	3316-3327	metalaxyl-M	abstract[215]|abstract[216]	giv[215]|giv[216]	coref	33-10[242_216]
28-20	3328-3336	exposure	abstract[215]|abstract[216]	giv[215]|giv[216]	_	_
28-21	3337-3338	.	_	_	_	_

#Text=Furthermore , the perturbation degrees induced by metalaxy-M were higher than rac -metalaxy in energy metabolism .
29-1	3339-3350	Furthermore	_	_	_	_
29-2	3351-3352	,	_	_	_	_
29-3	3353-3356	the	quantity[218]	new[218]	_	_
29-4	3357-3369	perturbation	abstract|quantity[218]	new|new[218]	_	_
29-5	3370-3377	degrees	quantity[218]	new[218]	_	_
29-6	3378-3385	induced	_	_	_	_
29-7	3386-3388	by	_	_	_	_
29-8	3389-3399	metalaxy-M	substance	new	_	_
29-9	3400-3404	were	_	_	_	_
29-10	3405-3411	higher	_	_	_	_
29-11	3412-3416	than	_	_	_	_
29-12	3417-3420	rac	substance|abstract[221]	giv|new[221]	coref	33-10
29-13	3421-3430	-metalaxy	abstract[221]	new[221]	_	_
29-14	3431-3433	in	abstract[221]	new[221]	_	_
29-15	3434-3440	energy	abstract[221]|substance|abstract[223]	new[221]|giv|giv[223]	coref	31-1[226_223]
29-16	3441-3451	metabolism	abstract[221]|abstract[223]	new[221]|giv[223]	_	_
29-17	3452-3453	.	_	_	_	_

#Text=3.3 .
30-1	3454-3457	3.3	abstract	new	_	_
30-2	3458-3459	.	_	_	_	_

#Text=Lipid Metabolism
31-1	3460-3465	Lipid	substance|abstract[226]	new|giv[226]	coref|coref	32-8|32-9[0_226]
31-2	3466-3476	Metabolism	abstract[226]	giv[226]	_	_

#Text=In this study , metalaxyl-M induced two lipid metabolism pathway fluctuations including glycerophospholipid metabolism , glyoxylate , and dicarboxylate metabolism .
32-1	3477-3479	In	_	_	_	_
32-2	3480-3484	this	abstract[227]	new[227]	_	_
32-3	3485-3490	study	abstract[227]	new[227]	_	_
32-4	3491-3492	,	_	_	_	_
32-5	3493-3504	metalaxyl-M	substance	giv	coref	34-6
32-6	3505-3512	induced	_	_	_	_
32-7	3513-3516	two	abstract[232]	new[232]	_	_
32-8	3517-3522	lipid	quantity|abstract[232]	giv|new[232]	coref	33-4
32-9	3523-3533	metabolism	abstract|abstract[232]	giv|new[232]	coref	32-13[234_0]
32-10	3534-3541	pathway	place|abstract[232]	new|new[232]	coref	33-3[240_0]
32-11	3542-3554	fluctuations	abstract[232]	new[232]	_	_
32-12	3555-3564	including	abstract[232]	new[232]	_	_
32-13	3565-3584	glycerophospholipid	abstract[232]|object|abstract[234]	new[232]|new|giv[234]	coref	32-19[237_234]
32-14	3585-3595	metabolism	abstract[232]|abstract[234]	new[232]|giv[234]	_	_
32-15	3596-3597	,	abstract[232]	new[232]	_	_
32-16	3598-3608	glyoxylate	abstract[232]|substance	new[232]|new	_	_
32-17	3609-3610	,	abstract[232]	new[232]	_	_
32-18	3611-3614	and	abstract[232]	new[232]	_	_
32-19	3615-3628	dicarboxylate	abstract[232]|substance|abstract[237]	new[232]|new|giv[237]	coref	33-5[0_237]
32-20	3629-3639	metabolism	abstract[232]|abstract[237]	new[232]|giv[237]	_	_
32-21	3640-3641	.	_	_	_	_

#Text=However , no lipid metabolism pathway was affected by rac -metalaxyl exposure .
33-1	3642-3649	However	_	_	_	_
33-2	3650-3651	,	_	_	_	_
33-3	3652-3654	no	place[240]	giv[240]	_	_
33-4	3655-3660	lipid	abstract|place[240]	giv|giv[240]	coref	36-7
33-5	3661-3671	metabolism	abstract|place[240]	giv|giv[240]	coref	36-7[258_0]
33-6	3672-3679	pathway	place[240]	giv[240]	_	_
33-7	3680-3683	was	_	_	_	_
33-8	3684-3692	affected	_	_	_	_
33-9	3693-3695	by	_	_	_	_
33-10	3696-3699	rac	substance|abstract[242]	giv|giv[242]	_	_
33-11	3700-3710	-metalaxyl	abstract[242]	giv[242]	_	_
33-12	3711-3719	exposure	abstract[242]	giv[242]	_	_
33-13	3720-3721	.	_	_	_	_

#Text=According to metabolomics data , metalaxyl-M induced the increased levels of choline and TMAO and decreased levels of PC and GPC .
34-1	3722-3731	According	_	_	_	_
34-2	3732-3734	to	_	_	_	_
34-3	3735-3747	metabolomics	abstract|abstract[244]	new|new[244]	_	_
34-4	3748-3752	data	abstract[244]	new[244]	_	_
34-5	3753-3754	,	_	_	_	_
34-6	3755-3766	metalaxyl-M	substance	giv	coref	39-14
34-7	3767-3774	induced	_	_	_	_
34-8	3775-3778	the	abstract[246]	new[246]	coref	39-1[285_246]
34-9	3779-3788	increased	abstract[246]	new[246]	_	_
34-10	3789-3795	levels	abstract[246]	new[246]	_	_
34-11	3796-3798	of	abstract[246]	new[246]	_	_
34-12	3799-3806	choline	abstract[246]|substance	new[246]|new	coref	37-1
34-13	3807-3810	and	abstract[246]	new[246]	_	_
34-14	3811-3815	TMAO	abstract[246]|substance	new[246]|new	_	_
34-15	3816-3819	and	abstract[246]	new[246]	_	_
34-16	3820-3829	decreased	abstract[246]|abstract[249]	new[246]|new[249]	_	_
34-17	3830-3836	levels	abstract[246]|abstract[249]	new[246]|new[249]	_	_
34-18	3837-3839	of	abstract[246]|abstract[249]	new[246]|new[249]	_	_
34-19	3840-3842	PC	abstract[246]|abstract[249]|substance|substance[251]	new[246]|new[249]|new|new[251]	coref|coref	39-16|39-16[292_251]
34-20	3843-3846	and	abstract[246]|abstract[249]|substance[251]	new[246]|new[249]|new[251]	_	_
34-21	3847-3850	GPC	abstract[246]|abstract[249]|substance[251]|substance	new[246]|new[249]|new[251]|new	coref	35-9
34-22	3851-3852	.	_	_	_	_

#Text=Rac -metalaxyl only induced the decreased level of GPC .
35-1	3853-3856	Rac	substance	new	_	_
35-2	3857-3867	-metalaxyl	_	_	_	_
35-3	3868-3872	only	_	_	_	_
35-4	3873-3880	induced	_	_	_	_
35-5	3881-3884	the	abstract[254]	new[254]	coref	36-14[261_254]
35-6	3885-3894	decreased	abstract[254]	new[254]	_	_
35-7	3895-3900	level	abstract[254]	new[254]	_	_
35-8	3901-3903	of	abstract[254]	new[254]	_	_
35-9	3904-3907	GPC	abstract[254]|substance	new[254]|giv	coref	39-18
35-10	3908-3909	.	_	_	_	_

#Text=Such metabolites were all related to lipid metabolism and had essential effect on cholesterol level in digestive system .
36-1	3910-3914	Such	substance[256]	giv[256]	coref	39-24[294_256]
36-2	3915-3926	metabolites	substance[256]	giv[256]	_	_
36-3	3927-3931	were	_	_	_	_
36-4	3932-3935	all	_	_	_	_
36-5	3936-3943	related	_	_	_	_
36-6	3944-3946	to	_	_	_	_
36-7	3947-3952	lipid	object|abstract[258]	giv|giv[258]	coref|coref	37-10|37-13[268_258]
36-8	3953-3963	metabolism	abstract[258]	giv[258]	_	_
36-9	3964-3967	and	_	_	_	_
36-10	3968-3971	had	_	_	_	_
36-11	3972-3981	essential	abstract[259]	new[259]	_	_
36-12	3982-3988	effect	abstract[259]	new[259]	_	_
36-13	3989-3991	on	abstract[259]	new[259]	_	_
36-14	3992-4003	cholesterol	abstract[259]|substance|abstract[261]	new[259]|new|giv[261]	_	_
36-15	4004-4009	level	abstract[259]|abstract[261]	new[259]|giv[261]	_	_
36-16	4010-4012	in	abstract[259]|abstract[261]	new[259]|giv[261]	_	_
36-17	4013-4022	digestive	abstract[259]|abstract[261]|organization|abstract[263]	new[259]|giv[261]|new|new[263]	_	_
36-18	4023-4029	system	abstract[259]|abstract[261]|abstract[263]	new[259]|giv[261]|new[263]	_	_
36-19	4030-4031	.	_	_	_	_

#Text=Choline is an important nutrient that is required for lipid transport , methyl-group metabolism , neurotransmitter synthesis , cell membrane structure , and signaling .
37-1	4032-4039	Choline	substance	giv	coref	37-3[265_0]
37-2	4040-4042	is	_	_	_	_
37-3	4043-4045	an	substance[265]	giv[265]	coref	38-4[0_265]
37-4	4046-4055	important	substance[265]	giv[265]	_	_
37-5	4056-4064	nutrient	substance[265]	giv[265]	_	_
37-6	4065-4069	that	_	_	_	_
37-7	4070-4072	is	_	_	_	_
37-8	4073-4081	required	_	_	_	_
37-9	4082-4085	for	_	_	_	_
37-10	4086-4091	lipid	abstract|abstract[267]	giv|new[267]	coref	38-27
37-11	4092-4101	transport	abstract[267]	new[267]	_	_
37-12	4102-4103	,	_	_	_	_
37-13	4104-4116	methyl-group	abstract[268]	giv[268]	coref	38-27[283_268]
37-14	4117-4127	metabolism	abstract[268]	giv[268]	_	_
37-15	4128-4129	,	_	_	_	_
37-16	4130-4146	neurotransmitter	abstract|abstract[270]	new|giv[270]	_	_
37-17	4147-4156	synthesis	abstract[270]	giv[270]	_	_
37-18	4157-4158	,	_	_	_	_
37-19	4159-4163	cell	abstract[272]	new[272]	_	_
37-20	4164-4172	membrane	object|abstract[272]	new|new[272]	coref	38-24[281_0]
37-21	4173-4182	structure	abstract[272]	new[272]	_	_
37-22	4183-4184	,	_	_	_	_
37-23	4185-4188	and	_	_	_	_
37-24	4189-4198	signaling	abstract	new	_	_
37-25	4199-4200	.	_	_	_	_

#Text=In addition , choline is a constituent of cell membranes and lipoprotein phospholipids , which play an important role in the integrity of cell membrane and lipid metabolism .
38-1	4201-4203	In	_	_	_	_
38-2	4204-4212	addition	_	_	_	_
38-3	4213-4214	,	_	_	_	_
38-4	4215-4222	choline	substance	giv	coref	38-6[275_0]
38-5	4223-4225	is	_	_	_	_
38-6	4226-4227	a	substance[275]	giv[275]	coref	39-2[0_275]
38-7	4228-4239	constituent	substance[275]	giv[275]	_	_
38-8	4240-4242	of	substance[275]	giv[275]	_	_
38-9	4243-4247	cell	substance[275]|object[276]	giv[275]|new[276]	coref	40-13[304_276]
38-10	4248-4257	membranes	substance[275]|object[276]	giv[275]|new[276]	_	_
38-11	4258-4261	and	substance[275]	giv[275]	_	_
38-12	4262-4273	lipoprotein	substance[275]|substance|object[278]	giv[275]|new|new[278]	_	_
38-13	4274-4287	phospholipids	substance[275]|object[278]	giv[275]|new[278]	_	_
38-14	4288-4289	,	_	_	_	_
38-15	4290-4295	which	_	_	_	_
38-16	4296-4300	play	_	_	_	_
38-17	4301-4303	an	abstract[279]	new[279]	_	_
38-18	4304-4313	important	abstract[279]	new[279]	_	_
38-19	4314-4318	role	abstract[279]	new[279]	_	_
38-20	4319-4321	in	abstract[279]	new[279]	_	_
38-21	4322-4325	the	abstract[279]|abstract[280]	new[279]|new[280]	_	_
38-22	4326-4335	integrity	abstract[279]|abstract[280]	new[279]|new[280]	_	_
38-23	4336-4338	of	abstract[279]|abstract[280]	new[279]|new[280]	_	_
38-24	4339-4343	cell	abstract[279]|abstract[280]|object[281]	new[279]|new[280]|giv[281]	coref	39-9[0_281]
38-25	4344-4352	membrane	abstract[279]|abstract[280]|object[281]	new[279]|new[280]|giv[281]	_	_
38-26	4353-4356	and	abstract[279]|abstract[280]	new[279]|new[280]	_	_
38-27	4357-4362	lipid	abstract[279]|abstract[280]|object|abstract[283]	new[279]|new[280]|giv|giv[283]	_	_
38-28	4363-4373	metabolism	abstract[279]|abstract[280]|abstract[283]	new[279]|new[280]|giv[283]	_	_
38-29	4374-4375	.	_	_	_	_

#Text=Increased choline levels in urine samples suggested the membrane fluidity was disrupted by metalaxyl-M . PC and GPC are known to be important endogenous metabolites related to maintenance of choline homeostasis and bile acids excretion .
39-1	4376-4385	Increased	abstract[285]	giv[285]	_	_
39-2	4386-4393	choline	abstract|abstract[285]	giv|giv[285]	coref	39-30
39-3	4394-4400	levels	abstract[285]	giv[285]	_	_
39-4	4401-4403	in	abstract[285]	giv[285]	_	_
39-5	4404-4409	urine	abstract[285]|substance|object[287]	giv[285]|giv|new[287]	_	_
39-6	4410-4417	samples	abstract[285]|object[287]	giv[285]|new[287]	_	_
39-7	4418-4427	suggested	_	_	_	_
39-8	4428-4431	the	substance[289]	new[289]	_	_
39-9	4432-4440	membrane	object|substance[289]	giv|new[289]	_	_
39-10	4441-4449	fluidity	substance[289]	new[289]	_	_
39-11	4450-4453	was	_	_	_	_
39-12	4454-4463	disrupted	_	_	_	_
39-13	4464-4466	by	_	_	_	_
39-14	4467-4478	metalaxyl-M	substance	giv	coref	41-19
39-15	4479-4480	.	_	_	_	_
39-16	4481-4483	PC	object|substance[292]	giv|giv[292]	coref|coref	40-3|40-3[301_292]
39-17	4484-4487	and	substance[292]	giv[292]	_	_
39-18	4488-4491	GPC	substance[292]|substance	giv[292]|giv	coref	40-6
39-19	4492-4495	are	_	_	_	_
39-20	4496-4501	known	_	_	_	_
39-21	4502-4504	to	_	_	_	_
39-22	4505-4507	be	_	_	_	_
39-23	4508-4517	important	_	_	_	_
39-24	4518-4528	endogenous	substance[294]	giv[294]	_	_
39-25	4529-4540	metabolites	substance[294]	giv[294]	_	_
39-26	4541-4548	related	_	_	_	_
39-27	4549-4551	to	_	_	_	_
39-28	4552-4563	maintenance	abstract[295]	new[295]	_	_
39-29	4564-4566	of	abstract[295]	new[295]	_	_
39-30	4567-4574	choline	abstract[295]|abstract|abstract[297]	new[295]|giv|new[297]	_	_
39-31	4575-4586	homeostasis	abstract[295]|abstract[297]	new[295]|new[297]	_	_
39-32	4587-4590	and	abstract[295]	new[295]	_	_
39-33	4591-4595	bile	abstract[295]|abstract[299]	new[295]|new[299]	_	_
39-34	4596-4601	acids	abstract[295]|substance|abstract[299]	new[295]|new|new[299]	_	_
39-35	4602-4611	excretion	abstract[295]|abstract[299]	new[295]|new[299]	_	_
39-36	4612-4613	.	_	_	_	_

#Text=Moreover , PC , and GPC are not only essential components of cell membranes , but also protect cell from oxidative stress and lipotoxicity .
40-1	4614-4622	Moreover	_	_	_	_
40-2	4623-4624	,	_	_	_	_
40-3	4625-4627	PC	object|substance[301]	giv|giv[301]	coref|coref	41-5|41-5[311_301]
40-4	4628-4629	,	substance[301]	giv[301]	_	_
40-5	4630-4633	and	substance[301]	giv[301]	_	_
40-6	4634-4637	GPC	substance[301]|substance	giv[301]|giv	coref	41-7
40-7	4638-4641	are	_	_	_	_
40-8	4642-4645	not	_	_	_	_
40-9	4646-4650	only	abstract[303]	new[303]	_	_
40-10	4651-4660	essential	abstract[303]	new[303]	_	_
40-11	4661-4671	components	abstract[303]	new[303]	_	_
40-12	4672-4674	of	abstract[303]	new[303]	_	_
40-13	4675-4679	cell	abstract[303]|object[304]	new[303]|giv[304]	_	_
40-14	4680-4689	membranes	abstract[303]|object[304]	new[303]|giv[304]	_	_
40-15	4690-4691	,	_	_	_	_
40-16	4692-4695	but	_	_	_	_
40-17	4696-4700	also	_	_	_	_
40-18	4701-4708	protect	_	_	_	_
40-19	4709-4713	cell	place	new	_	_
40-20	4714-4718	from	_	_	_	_
40-21	4719-4728	oxidative	abstract|abstract[307]	new|new[307]	coref|coref	41-13|41-13[315_307]
40-22	4729-4735	stress	abstract[307]	new[307]	_	_
40-23	4736-4739	and	_	_	_	_
40-24	4740-4752	lipotoxicity	substance	new	coref	41-16
40-25	4753-4754	.	_	_	_	_

#Text=The decreased levels of PC and GPC may be good indicators of oxidative stress and lipotoxicity induced by metalaxyl-M .
41-1	4755-4758	The	abstract[309]	new[309]	coref	41-10[313_309]
41-2	4759-4768	decreased	abstract[309]	new[309]	_	_
41-3	4769-4775	levels	abstract[309]	new[309]	_	_
41-4	4776-4778	of	abstract[309]	new[309]	_	_
41-5	4779-4781	PC	abstract[309]|substance|substance[311]	new[309]|giv|giv[311]	_	_
41-6	4782-4785	and	abstract[309]|substance[311]	new[309]|giv[311]	_	_
41-7	4786-4789	GPC	abstract[309]|substance[311]|substance	new[309]|giv[311]|giv	_	_
41-8	4790-4793	may	_	_	_	_
41-9	4794-4796	be	_	_	_	_
41-10	4797-4801	good	abstract[313]	giv[313]	_	_
41-11	4802-4812	indicators	abstract[313]	giv[313]	_	_
41-12	4813-4815	of	abstract[313]	giv[313]	_	_
41-13	4816-4825	oxidative	abstract[313]|abstract|abstract[315]	giv[313]|giv|giv[315]	_	_
41-14	4826-4832	stress	abstract[313]|abstract[315]	giv[313]|giv[315]	_	_
41-15	4833-4836	and	abstract[313]	giv[313]	_	_
41-16	4837-4849	lipotoxicity	abstract[313]|substance	giv[313]|giv	_	_
41-17	4850-4857	induced	_	_	_	_
41-18	4858-4860	by	_	_	_	_
41-19	4861-4872	metalaxyl-M	substance	giv	_	_
41-20	4873-4874	.	_	_	_	_
